Inovio Pharmaceuticals is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Type
Public
HQ
Blue Bell, US
Founded
1979
Size (employees)
239 (est)
Website
inovio.com
Inovio Pharmaceuticals was founded in 1979 and is headquartered in Blue Bell, US
Report incorrect company information

Key People/Management at Inovio Pharmaceuticals

J. Joseph Kim

J. Joseph Kim

CEO
Peter Kies

Peter Kies

CFO
Niranjan Sardesai

Niranjan Sardesai

COO
Mark Bagarazzi

Mark Bagarazzi

Chief Medical Officer
Show more

Inovio Pharmaceuticals Office Locations

Inovio Pharmaceuticals has offices in San Diego and Blue Bell
Blue Bell, US (HQ)
1787 Sentry Parkway West
San Diego, US
6769 Mesa Ridge Rd
San Diego, US
10480 Wateridge Cir
Show all (3)
Report incorrect company information

Inovio Pharmaceuticals Financials and Metrics

Inovio Pharmaceuticals Revenue

Inovio Pharmaceuticals's revenue was reported to be $42.22 m in FY, 2017
USD

Revenue (Q2, 2018)

26 m

Net income (Q2, 2018)

(39 m)

EBIT (Q2, 2018)

(37.9 m)

Market capitalization (16-Aug-2018)

411.7 m

Closing stock price (16-Aug-2018)

4.5

Cash (30-Jun-2018)

15.1 m
Inovio Pharmaceuticals's current market capitalization is $411.7 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

13.5 m10.5 m40.6 m8.5 m42.2 m

Revenue growth, %

(22%)288%(79%)

General and administrative expense

28.3 m

R&D expense

98.6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

9.5 m2.4 m3.8 m1.8 m5.2 m5.3 m24.2 m8.1 m6.2 m12.5 m10.4 m20.4 m1.5 m26 m

General and administrative expense

3.3 m4.1 m4.3 m3.2 m4.1 m4.7 m4.4 m5.4 m5.8 m5.8 m7.8 m6.2 m9.7 m16.9 m

R&D expense

5.4 m8.2 m9.6 m7 m9.4 m16.7 m16.1 m18.2 m19.6 m27 m24.5 m23.9 m24.6 m47 m

Operating expense total

8.7 m12.4 m14 m10.2 m13.5 m20.4 m20.5 m23.6 m24.4 m32.7 m32.3 m30 m34.3 m63.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

33.7 m40.5 m57.6 m19.1 m23.8 m

Accounts Receivable

3.3 m2.8 m7.3 m15.8 m6 m

Inventories

637.4 k798 k917.3 k1.7 m

Current Assets

58.7 m98.9 m171.9 m124.6 m138.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

33.1 m98.8 m88.5 m70.7 m26.1 m70.3 m85.5 m41.6 m28.5 m23.3 m22.9 m23.9 m37.5 m15.1 m

Accounts Receivable

10.6 m2.7 m2.9 m1.6 m3.3 m5.6 m11 m11.2 m10.4 m17.5 m9.9 m7.5 m5.1 m1.7 m

Current Assets

57.9 m121.7 m112.9 m104.6 m87.3 m162.1 m184.1 m160.6 m148 m140.2 m106.8 m106.9 m123.8 m101.8 m

PP&E

17.5 m16.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(66.1 m)(36.1 m)(29.1 m)(73.7 m)(88.2 m)

Depreciation and Amortization

2.1 m1.6 m1.9 m3.1 m1.9 m

Inventories

(229.7 k)(160.5 k)(119.3 k)(831.8 k)

Accounts Payable

2.2 m1.5 m6.5 m6.4 m2.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(30.9 m)(10.8 m)(10.7 m)(7.2 m)(10.6 m)(6.2 m)5.6 m(8 m)(18.7 m)(20.8 m)(32.4 m)(39 m)

Depreciation and Amortization

1.3 m2.6 m

Accounts Payable

5.3 m4.7 m4.4 m6.1 m10.5 m12.1 m12.7 m16.2 m14.5 m(6.4 m)(9.4 m)

Cash From Operating Activities

(12.6 m)(31.6 m)
USDY, 2018

Financial Leverage

1.3 x
Show all financial metrics

Inovio Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

620
Show all operating metrics
Report incorrect company information

Inovio Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Inovio Pharmaceuticals Company Life and Culture

Report incorrect company information